The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer

Abstract

CLC Number:

R734.2

ZHAO Yan, ZHANG Ru. The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer [J]. Chinese Journal of Pharmacovigilance, 2010, 7(10): 617-619.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2010/V7/I10/617

[1] American Cancer Society. Cancer Facts and Figures 2008 [EB/OL]. 2009-07-13[2010-06-25].http://www.cancer.org/downloads/STT/ 2008CAFFfinalsecured.pdf.
[2] World Health Organization. Fact Sheet No. 310[EB/OL]. 2009-0713[2010-06-25]. http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
[3] Postmus P E, Smit E F. Chemotherapy for brain metastases of lung cancer: a Review[J]. Ann Oncol, 1999, 10(7): 753-759.
[4] Endelsohn J, Baselga J. Status of the epidermal growth factor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003,21(14): 2787-2799.
[5] Herbst R S, ShinD M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy[J]. Cancer,2002, 94(5): 1593-1611.
[6] Metro G, Finocchiaro G, Cappuzzo F. Anti-cancer therapy with EGFR inhibitors:factors of prognostic and predictive significance[J]. Ann Oncol,2006,17(suppl 2):842-845.
[7] Mok T, Wu Y-L, Thongprasert S, et al. Phase III, randomized, open-label , first-line study of gefitinib ( G ) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer(NSCLC) [J]. Ann Oncol,2008,19 (suppl 8): 1-4.
[8] Hirsch F R, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis[J].J Clin Oncol,2003,21:3798-3807.
[9] Hirsch F R, Varella-Garcia M, Bunn P A Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer[J]. J Clin Oncol,2006, 24:5034-5042.
[10] Tsao M S, Sakurada A, Cutz J C, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome[J]. N Engl J Med,2005, 353:133-144.
[11] ShepherdF A, RodriguesP J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer[J].N Engl J Med, 2005, 353(2): 123-132.
[12] Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from “never smokers”and are associated with sensitivity of tumors to gefi tinib and erlotinib [J]. Proc Natl Acad Sci USA, 2004, 101(36):13306-13311.

[1]	XIE Rui, GENG Zihan, BAO Lei, ZHAO Ronghua, LI Shuran, SUN Qiyue, WANG Xinwei, ZHANG Jingsheng, CUI Xiaolan, GUO Shanshan, SUN Jing. Research Progress in Pharmacological Actions, Mechanisms, Structural Modifications and Targeted Formulations of Ribavirin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 950-955.
[2]	WANG Yinghe, LI Mingqi, ZHAO Xiaolu, MA Yuehong. Different Functions of Autophagy in Diseased Livers [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 956-960.
[3]	LIU Ming, ZHENG Li, ZHANG Weina, SUN Xuelin, TIAN Jinhui, ZHAO Yan. Research Progress in Biological Activity and Mechanisms of Pachymic Acid [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 826-830.
[4]	ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo. Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835.
[5]	GAO Caiyun, WANG Boyuan, GAO Xiaojie. Research Progress in Correlations between SGLT2 Inhibitors and Malignant Tumors [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 836-840.
[6]	CAO Weiping, ZHANG Shichao, NI Xia, XIE Bing, WANG Xinzhi, XING Mengtao. Research Progress in Liver Injury Caused by Drugs Commonly Used during Pregnancy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 528-531.
[7]	BU Zixuan, XUE Mengwei, TIAN Jiawei, KE Kaile, WANG Ziying, LI Xiao, LU Tiangong. Interventions of Guizhi Fuling Pills in Properties of Ovarian Cancer Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 263-270.
[8]	TANG Qianhui, ZHANG Haoran, ZHANG Luyong, JIANG Zhenzhou. Research Progress in Triptolide-Induced Live Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 121-127.
[9]	PEI Yusheng, XU Lin, ZHAO Yuxin, CAI Tong, HUA Xiaodong. Low Endotoxin Recovery and Mitigation Strategies [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 72-75.
[10]	LI Xinlei, GONG Leilei, WANG Xiaoxia, ZHANG Xueyan, ZHAO Han, YAO Weijie, YUAN Sisi, FENG Xin. Molecular mechanism of Yangxue Antai granules for the treatment of recurrent spontaneous abortion based on network pharmacology and molecular docking [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 366-370.
[11]	SUN Qiyue, GUO Shanshan, ZHAO Ronghua, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Research progress on animal models of allergic rhinitis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 241-245.
[12]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[13]	XIN Lingyi, YANG Yang, ZHU Jing, HE Na, ZHANG Jingmei, WANG Hangtian, CHEN Qinhua, YANG Guangyi. Classification of anti-tumor active ingredients of Paridis Rhizoma and research progress in mechanisms of action [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 235-240.
[14]	ZHENG Enqi, BAI Xue. Analysis and Research on the Mechanism of Cerebral Ischemia in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1398-1404.
[15]	LIU Zhejun, TANG Tian, TAN Tianyang, BAI Xue. Research Progress on Traditional Chinese Medicine Compound Formulae against Hemorrhagic Stroke [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1405-1410.

The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics